Compare Mesoblast Limited (MESO) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Clear Secure Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Clear Secure Inc trades at $43.54 (market cap $4.44B). The key difference: Clear Secure Inc is far larger — about 2.5× Mesoblast Limited's market cap, and Clear Secure Inc pays a 1.33% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Clear Secure Inc for 19 Days on average.
| MESO | YOU | |
|---|---|---|
Market Cap | $1.75B | $4.44B |
Volume | 239,027 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $20.96 | $62.36 |
52-Week Low | $13.19 | $29.61 |
Typical Hold Time | 14 Days | 19 Days |
Enterprise Value | $1.83B | $3.59B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Clear Secure (YOU) trades at $42.58, up 2.6% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 27% revenue growth in Q2 2026, beating earnings estimates, and robust profitability metrics including 66.7% gross margin and 90.3% ROE. Recent partnership with CrowdStrike and corporate membership launch highlight growth initiatives.
The stock offers 44% upside to the $61.40 consensus target with analyst sentiment divided equally between Buy and Hold. Key risks include competitive pressures and execution of expansion plans. Strong cash flow generation and accelerating membership growth support the bullish case, though valuation multiples remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
